OncoMatch/Clinical Trials/NCT06055959
A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis
Is NCT06055959 recruiting? Yes, currently enrolling (May 2026). This Phase 2/3 trial studies Zilucoplan for generalized myasthenia gravis.
Treatment: Zilucoplan — The purpose of this study is to assess the pharmacokinetics, pharmacodynamics, safety, tolerability, immunogenicity and activity of zilucoplan (ZLP) in pediatric study participants with generalized myasthenia gravis (gMG).
Check if I qualifyExtracted eligibility criteria
Biomarker criteria
Required: CHRNA1 positive serologic test
diagnosis of generalized myasthenia gravis (gMG) confirmed by a prior positive serologic test result to acetylcholine receptor (AChR)
Excluded: MUSK positive serology
Participant has known positive serology for muscle-specific kinase
Disease stage
Required: Stage MGFA II, MGFA III, MGFA IV (MGFA Clinical Classification)
Excluded: Stage MINIMAL MANIFESTATION STATUS
Participant meets the criteria as defined by the Myasthenia Gravis Foundation of America (MGFA) Clinical Classification II to IV at Screening
Prior therapy
Cannot have received: thymectomy
Participant has had a thymectomy within 6 months prior to Baseline
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Mg0014 50168 · Chicago, Illinois
- Mg0014 50574 · Flower Mound, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify